SLC22A16

Solute carrier family 22 member 16 · Q86VW1 · SLC22A16 on Sugi Atlas →

1,562 patent compounds predicted against SLC22A16, 1,211 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Levocarnitine (SCHEMBL21970)	1.00	1/20
Carnitine (SCHEMBL21971)	1.00	1/20
D-Carnitine (SCHEMBL94286)	1.00	1/20
Carnitine (SCHEMBL1813524)	1.00	1/20
Carnitine (SCHEMBL3902633)	1.00	1/20
Levocarnitine (SCHEMBL4593172)	1.00	1/20
Carnitine (SCHEMBL308278)	0.95	1/20
Carnitine (SCHEMBL308279)	0.95	1/20
Levocarnitine (SCHEMBL309626)	0.95	1/20
Carnitine (SCHEMBL357560)	0.95	1/20
Levocarnitine (SCHEMBL388330)	0.95	1/20
Carnitine (SCHEMBL1456180)	0.95	1/20
Carnitine (SCHEMBL1456305)	0.95	1/20
Carnitine (SCHEMBL1456306)	0.95	1/20
Carnitine (SCHEMBL1719821)	0.95	1/20
Levocarnitine (SCHEMBL2508292)	0.95	1/20
Levocarnitine (SCHEMBL3007083)	0.95	1/20
Carnitine (SCHEMBL4748604)	0.95	1/20
Levocarnitine (SCHEMBL5747102)	0.95	1/20
Levocarnitine (SCHEMBL5747106)	0.95	1/20

Clinical trials — most relevant to SLC22A16 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome	PHASE2	RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia	nan	COMPLETED
Oxalate and Citrate	nan	RECRUITING
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response	nan	COMPLETED
SLC6A1-NDD Prospective Longitudinal Natural History Study	nan	NOT_YET_RECRUITING
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Autonomic Function in Patients With COPD	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SLC22A16 binder may also engage these)

Protein	Name	Similarity
Q17QN9	—	1.000	Q17QN9 →
Q66KG0	—	0.996	Q66KG0 →
Q91WU2	—	0.984	Q91WU2 →
Q95R48	—	0.983	Q95R48 →
Q9WTW5	—	0.983	Q9WTW5 →
O88446	—	0.982	O88446 →
Q9WTN6	—	0.982	Q9WTN6 →
Q9U539	—	0.982	Q9U539 →
Q9R1U7	—	0.980	Q9R1U7 →
B2GV36	—	0.980	B2GV36 →
Q10917	—	0.979	Q10917 →
P38142	—	0.977	P38142 →
Q961J5	—	0.977	Q961J5 →
Q9R0W2	—	0.977	Q9R0W2 →
Q9JJL3	—	0.976	Q9JJL3 →
Q91YY5	—	0.976	Q91YY5 →
Q99J94	—	0.976	Q99J94 →
Q66J54	—	0.976	Q66J54 →
Q9VIK2	—	0.975	Q9VIK2 →
O88909	—	0.975	O88909 →
Q8HYW2	—	0.975	Q8HYW2 →
Q9R141	—	0.975	Q9R141 →
O35913	—	0.974	O35913 →
P46720	—	0.974	P46720 →
O76082	—	0.974	O76082 →
SLC22A3	Solute carrier family 22 member 3	0.974	landscape →
Q9Z306	—	0.974	Q9Z306 →
Q7TMR7	—	0.974	Q7TMR7 →
Q9NYB5	—	0.973	Q9NYB5 →
Q9QZX8	—	0.973	Q9QZX8 →